Lepu Biopharma Co. Ltd. Class H (2157) AI Stock Analysis

• Market Cap: HK$11.52B
• Dividend Yield: N/A
• Average Volume (3M): 13.90M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: 240.05%
• EPS Growth: -140.09%
• Country: HK
• Employees: 498
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.02
• Shares Outstanding: 1,804,439,800
• 10 Day Avg. Volume: 11,565,494
• 30 Day Avg. Volume: 13,902,953
• PEG Ratio: >-0.01
• Price to Book (P/B): 5.92
• Price to Sales (P/S): 11.31
• P/FCF Ratio: -16.11
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: HK$6.00 ▼(-7.26% Downside)

The overall stock score is primarily impacted by the company's weak financial performance and valuation metrics. The negative profitability and high leverage pose significant risks. Additionally, technical indicators suggest a bearish trend, further contributing to the low score. The absence of earnings call data and corporate events did not influence the score.

Lepu Biopharma Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Lepu Biopharma Co. Ltd. Class H (2157) is a biopharmaceutical company focused on the research, development, and commercialization of innovative oncology drugs. The company operates primarily in the biotechnology and pharmaceutical sectors, aiming to deliver high-quality healthcare solutions to address unmet medical needs in cancer treatment. Its product portfolio includes a range of targeted therapies and biological medicines designed to improve patient outcomes.

How the Company Makes Money

Lepu Biopharma Co. Ltd. generates revenue through the development and sale of its oncology drugs. The company's primary revenue streams include sales of its proprietary pharmaceutical products, licensing agreements, and collaborations with other pharmaceutical companies for joint development and commercialization of treatments. Additionally, Lepu Biopharma may receive milestone payments and royalties from partners as part of its strategic partnerships. By focusing on innovative and effective cancer therapies, the company seeks to capture a significant share of the growing market for oncology treatments.

Lepu Biopharma Co. Ltd. Class H Financial Statement Overview

Summary

Lepu Biopharma Co. Ltd. faces significant challenges in achieving profitability and maintaining financial stability. Despite revenue growth, the company's negative margins and high leverage indicate operational and financial risks. The negative cash flow position further underscores the need for strategic improvements to enhance liquidity and reduce reliance on debt financing.

Income Statement

The company has shown growth in total revenue from 2022 to 2024, with a significant increase in 2024. However, profitability remains a challenge with consistently negative net income, leading to negative net profit margins. The gross profit margin is strong at 79.65% for 2024, but the EBIT and EBITDA margins are negative, pointing to operational inefficiencies.

Balance Sheet

The company's balance sheet reflects a high level of debt with a debt-to-equity ratio of 1.20 in 2024, indicating potential leverage risk. Stockholders' equity has decreased over the years, affecting the equity ratio negatively. The company has sufficient cash reserves, but the decline in equity raises concerns about financial stability.

Cash Flow

Cash flow from operations is consistently negative, and free cash flow has also remained negative, reflecting challenges in generating cash from core activities. This poses a risk to the company's liquidity position, as it may need to rely on external financing for operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	700.45M	367.79M	225.35M	15.57M	0.00	0.00
Gross Profit	619.27M	292.97M	197.07M	13.57M	0.00	0.00
EBITDA	-72.37M	-311.94M	86.95M	-596.53M	-865.23M	-383.76M
Net Income	-177.20M	-411.38M	-22.10M	-689.05M	-1.01B	-581.85M
Balance Sheet
Total Assets	2.36B	2.28B	2.38B	2.53B	2.08B	2.42B
Cash, Cash Equivalents and Short-Term Investments	536.34M	464.91M	489.64M	678.20M	205.17M	761.40M
Total Debt	917.81M	850.16M	746.82M	690.30M	335.26M	203.08M
Total Liabilities	1.65B	1.60B	1.50B	1.63B	1.23B	921.89M
Stockholders Equity	745.26M	702.83M	896.90M	900.76M	836.71M	1.47B
Cash Flow
Free Cash Flow	-102.02M	-258.14M	-292.04M	-591.38M	-835.12M	-724.51M
Operating Cash Flow	-81.26M	-196.39M	-250.84M	-480.93M	-621.74M	-422.69M
Investing Cash Flow	-38.13M	-61.75M	18.26M	-74.66M	-3.89M	-749.67M
Financing Cash Flow	0.00	232.08M	-11.01M	1.03B	380.31M	1.39B

Lepu Biopharma Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.47
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2157, the sentiment is Negative. The current price of 6.47 is below the 20-day moving average (MA) of 6.82, below the 50-day MA of 7.71, and above the 200-day MA of 5.49, indicating a neutral trend. The MACD of -0.40 indicates Negative momentum. The RSI at 38.76 is Neutral, neither overbought nor oversold. The STOCH value of 32.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2157.

Lepu Biopharma Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2315	―	HK$10.27B	71.83	16.13%	―	48.38%	―
2171	―	HK$9.98B	―	-42.46%	―	1219.19%	25.15%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1672	―	HK$9.11B	-32.00	-12.74%	―	-76.58%	-4.90%
2162	―	HK$16.10B	―	-8.79%	―	964.40%	65.90%
1541	―	HK$8.54B	―	-53.23%	―	29639.67%	23.30%
2157	―	HK$11.52B	-55.06	-21.42%	―	240.05%	-140.09%

Lepu Biopharma Co. Ltd. Class H Corporate Events

Lepu Biopharma Reports First Profitable Half-Year and Advances Oncology Pipeline

Lepu Biopharma Co., Ltd. reported significant financial growth for the first half of 2025, achieving a revenue of approximately RMB465.9 million, which is 3.5 times higher than the same period in 2024, and marking its first profitable period with a profit of RMB29.3 million. The company is advancing its drug pipeline, with MRG003 nearing approval for NPC treatment and other key candidates like MRG004A and MRG006A progressing through various clinical trial stages, indicating a strong focus on expanding its market presence in oncology.

The most recent analyst rating on (HK:2157) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on Lepu Biopharma Co. Ltd. Class H stock, see the HK:2157 Stock Forecast page.

Lepu Biopharma Reports First-Ever Profit Amid Revenue Surge

Lepu Biopharma Co., Ltd. announced a positive profit alert, expecting a profit of not less than RMB24 million for the first half of 2025, marking a significant turnaround from a loss of approximately RMB197.0 million in the same period of 2024. This improvement is attributed to substantial revenue growth driven by increased sales of PUYOUHENG and income from a licensing collaboration with ArriVent BioPharma, Inc. The announcement indicates a strong operational performance and potential positive implications for stakeholders, although the results are preliminary and subject to finalization.

Lepu Biopharma Announces Upcoming Board Meeting to Review Interim Results

Lepu Biopharma Co., Ltd. has announced that its board of directors will hold a meeting on August 20, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The board will also consider recommending the payment of an interim dividend and address other business matters. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential dividend payouts, which could impact investor confidence and market positioning.

Lepu Biopharma Enters Licensing Deal with Excalipoint to Expand Global Reach

Lepu Biopharma Co., Ltd. announced a significant licensing transaction with Excalipoint, granting them exclusive rights to develop and commercialize two pre-clinical assets worldwide. This strategic move is part of Lepu Biopharma’s long-term strategy to globalize its pipeline and technologies, allowing the company to focus on advancing its research priorities and accelerating the commercialization of late-stage products. The deal includes an upfront payment of $10 million, potential milestone payments up to $847.5 million, and sales royalties. Additionally, Excalipoint will conduct a series A financing round, raising $41 million, which complements the licensing transaction and supports the company’s growth strategy.